Advanced therapeutics CDMO, ReciBioPharm and Hongene Biotech have entered into a drug manufacturing collaboration.
The partnership will look to enhance the gene-editing drug manufacturing process, through Hongene's proprietary technology for single-guide RNA (sgRNA) synthesis.
The method, according to ReciBioPharm, will reduce the presence of impurities in the product yield compared to conventional production methods.
The companies hope to elevate the quality of their therapies through this strategy.
ReciBioPharm and Hongene's alliance will allow the former to expand its service porfolio to include sgRNA manufacturing on top of its current mRNA, LNP and fill-finish services.
Through this initiative, the companies aim to streamline the gene therapy development and manufacturing process, while also dimishing the logistical complexities of dealing with multiple CDMOs.
Vikas Gupta, President of ReciBioPharm, stated: "Our collaboration with Hongene Biotech marks an important step forward for ReciBioPharm, enabling us to offer comprehensive, seamless solutions in the rapidly evolving gene editing sector. The combination of Hongene’s high-quality raw materials and synthesis methods with our capabilities will provide our clients with an unmatched portfolio of services in this developing field."
Echoing the sentiment, Wei Jiang, CEO at Hongene Biotech, added: "Our partnership with ReciBioPharm is set to redefine the manufacturing space for gene editing. Our cutting-edge sgRNA synthesis technology, combined with ReciBioPharm's expertise in end-to-end mRNA and drug product manufacture, promises to bring a unique solution that has significant value to the healthcare field."
